Acumen Pharmaceuticals, Inc. (ABOS) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Newton, VA, アメリカ. 現CEOは James Doherty.
ABOS を有する IPO日 2021-07-01, 61 名の正社員, に上場 NASDAQ Global Select, 時価総額 $162.34M.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
